Atalanta Therapeutics

Congratulations to Atalanta co-founder Dr. Anastasia Khvorova, on winning the 2025 Else Kröner Fresenius Prize for Medical Research, for her groundbreaking work in RNA-based therapies. The $2.7 million award is one of the largest research prizes in the world. She plans to use the prize to further her RNA research. Congratulations Anastasia for this achievement.

We are proud to announce the publication of our latest preclinical study results in the journal Epilepsia. Our groundbreaking research on KCNT1-related epilepsy demonstrates the potential of ATL-201 to significantly suppress seizures through 6 months. This study highlights our commitment to pioneering innovative treatments for severe neurological disorders and brings us one step closer to transforming the lives of people impacted by KCNT1 epilepsy. Read more about our findings here: https://bit.ly/3EduCeA #AtalantaTX

Stefan McDonough, Ph.D. presented mechanistic details on the antiseizure activity of Atalanta’s KCNT1-targeted di-siRNA ATL-201, results promising for treatment of a severe developmental epileptic encephalopathy and for the wider application of di-siRNA to disorders of the brain. The CNS distribution and durability of di-siRNA were also featured in a panel discussion on the critical themes and emerging potential of oligonucleotide therapies. #AtalantaTX #RNALeaders

We glided across the ice for a great cause! Atalanta Therapeutics was proud to sponsor and participate in the Curling for Cure event at Broomstones Curling Club, supporting research for Huntington's Disease. We remain committed to advancing potential therapies for Huntington's and other neurological disorders. A huge thank you to the Huntington's Disease Society of America (HDSA) for their incredible work! #AtalantaTX #HDSA

February 28th is Rare Disease Day, recognizing the millions of individuals around the world who are impacted by a rare disease. Yesterday, we joined the Rare Disease Day Walk in the Seaport with our biotech colleagues. It was inspiring to see everyone come together, donning their zebra stripes, to raise awareness and show support for those affected by rare diseases. The zebra stripes symbolize the uniqueness and rarity of these conditions. Together, we are committed to making significant strides in the ongoing fight against rare diseases, ensuring no one faces these challenges alone. #RareDiseaseDay #ShowYourStripes #TogetherWeCan

We are excited to share that our President and CEO, Alicia Secor, will be presenting at BioCapital Europe 2025 on February 6th at 12pm CET. Join us to learn more about Atalanta Therapeutics innovative pipeline and our mission to pioneer new treatment options for CNS diseases with our di-siRNA platform. #BioCapital2025 #AtalantaTX

We are thrilled to announce the successful closing of our oversubscribed $97 million Series B financing. The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from RiverVest Venture Partners, Novartis Venture Fund, funds managed by abrdn, Pictet Group, Mirae Asset Financial Group, and GHR Foundation alongside existing investor F-Prime Capital.    We thank our investors, team, and community partners who are joining Atalanta Therapeutics’ mission to advance RNAi medicines for serious neurological diseases. https://bit.ly/40Q603V #EQTLifeScience #SanofiVentures #FPrime #abrdn #RiverVest #GHRFoundation #NovartisVentureFund #Pictet #MiraeAsset #SeriesBFinancing #AtalantaTX 

Bruno MDC Godinho delivered a presentation on the cutting-edge role of di-siRNAs in neurodegenerative disease at the 6th Annual CNS Drug Delivery Summit in Boston. His talk offered a unique perspective on how RNA-based therapies can revolutionize the treatment landscape for neurodegenerative conditions and bring new hope for patients suffering from these debilitating diseases. #AtalantaTX

Benjamin Andreone, Ph.D. and Jennifer M. Lin, Ph.D. recently presented a poster at the American Epilepsy Society highlighting our latest data on our ATL-201 program for KCNT1-mediated epilepsy demonstrating that it effectively and durably suppresses or eliminates seizures in a mouse model of KCNT1-related epilepsy. A link to the poster can be found here: https://bit.ly/3ZWallL #AES #KCNT1 #AtalantaTX

Serena Hung, Atalanta’s Chief Medical Officer, recently provided an update on our progress with ATL-101 at the Innovation Forum at the Huntington Study Group (HSG) Meeting in Cincinnati, Ohio.  #AtalantaTX